Clinical chemistries

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study

Anti-miR-33 treatment showed no apparent toxicity over 12 weeks as demonstrated by clinical chemistries, blood counts, coagulation markers, body weights, and serum cytokine profiles all remaining with

Effect: null; all parameters within normal limits throughout the study